SCHEMBL548500

SCHEMBL548500

CCCCc1ccc(-c2ccc(O)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.73
ALDH1A1 P00352 3/20 0.73
HSD17B10 Q99714 3/20 0.73
ADRA2A P08913 2/20 0.73
ADORA3 P0DMS8 2/20 0.73
TACR2 P21452 2/20 0.73
SLC6A2 P23975 2/20 0.73
SLC6A4 P31645 2/20 0.73
SLC6A3 Q01959 2/20 0.73
KDM4E B2RXH2 1/20 0.73
LMNA P02545 1/20 0.73
SHBG P04278 1/20 0.73
TP53 P04637 1/20 0.73
CYP3A4 P08684 1/20 0.73
HSPD1 P10809 1/20 0.73
ADRB3 P13945 1/20 0.73
HTR2C P28335 1/20 0.73
HSPE1 P61604 1/20 0.73
HIF1A Q16665 1/20 0.73
TST Q16762 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL324185 0.98 ESR1 (0.70) ESR1ALDH1A1HSD17B10ADRA2AADORA3
SCHEMBL7253630 0.94 PTGS2 (0.84) ESR1ALDH1A1HSD17B10ADRA2AADORA3
SCHEMBL982418 0.94 PTGS2 (0.84) ESR1ALDH1A1HSD17B10ADRA2AADORA3
SCHEMBL20233 0.93 ESR1 (0.83) ESR1ALDH1A1HSD17B10ADRA2AADORA3
SCHEMBL981447 0.92 PTGS2 (0.88) ESR1ALDH1A1HSD17B10ADRA2AADORA3
SCHEMBL982001 0.92 PTGS2 (0.88) ESR1ALDH1A1HSD17B10ADRA2AADORA3
SCHEMBL981893 0.92 PTGS2 (0.88) ESR1ALDH1A1HSD17B10ADRA2AADORA3
SCHEMBL9227876 0.92 PTGS2 (0.88) ESR1ALDH1A1HSD17B10ADRA2AADORA3
SCHEMBL982373 0.92 PTGS2 (0.88) ESR1ALDH1A1HSD17B10ADRA2AADORA3
SCHEMBL7934900 0.92 PTGS2 (0.88) ESR1ALDH1A1HSD17B10ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 522 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3053992-A1 Biodiesel LANXESS Deutschland GmbH (DE) 2016-08-10 EP claimed
US-20260125569-A1 WHITE INKJET INK HEWLETT PACKARD DEVELOPMENT CO L P (US) 2026-05-07 US disclosed
US-12606716-B2 Biocide composition HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) 2026-04-21 US disclosed
EP-4417653-B1 QUINACRIDONE PIGMENT, PIGMENT DISPERSION, AND AQUEOUS INKJET INK DAINIPPON INK & CHEMICALS (JP) 2026-03-04 EP disclosed
EP-4100569-B1 INKJET INK FOR TEXTILE PRINTING HEWLETT PACKARD DEVELOPMENT CO (US) 2026-01-28 EP disclosed
US-12534632-B2 Aqueous ink composition, printed material, and method of producing printed material DIC CORPORATION (JP) 2026-01-27 US disclosed
EP-4653503-A1 METHOD FOR PRODUCING PIGMENT COMPOSITION, PIGMENT COMPOSITION, INK, AND PRINTED MATERIAL DIC Corporation (JP) 2025-11-26 EP disclosed
US-20250340749-A1 AQUEOUS PIGMENT DISPERSION AND PRODUCTION METHOD FOR AQUEOUS PIGMENT DISPERSION DIC CORPORATION (JP) 2025-11-06 US disclosed
EP-4640783-A1 TWO-PART CURABLE ADHESIVE, MULTILAYER BODY AND PACKAGE DIC Corporation (JP) 2025-10-29 EP disclosed
US-12454624-B2 Inkjet ink for textile printing HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) 2025-10-28 US disclosed
US-6245832-B1 WATER SOLUTION FUJI XEROX CO., LTD (JP) 2001-06-12 US disclosed
US-6235786-B1 RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS ABBOTT LABORATORIES 2001-05-22 US disclosed
US-6153001-A CONTROLLING PARTICLE SIZE; SURFACE TENSION; STORAGE STABILITY FUJI XEROX CO., LTD. (JP) 2000-11-28 US disclosed
CN-1261876-A N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases ABBOTT LAB (US) 2000-08-02 CN disclosed
EP-1001930-A2 N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES Abbott Laboratories (US) 2000-05-24 EP disclosed
US-6051645-A COMPRISING WATER, PIGMENT, WATER SOLUBLE ORGANIC SOLVENT, AND PLURALITY OF DISPERSANTS EACH HAVING A DIFFERENT HLB AND RESPECTIVE WEIGHTS TO SATISFY A GIVEN FORMULA; NONCLOGGING, DISPERSION STABILITY, HIGH RESOLUTION FUJI XEROX CO., LTD. (JP) 2000-04-18 US disclosed
WO-1999006361-A2 N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES ABBOTT LABORATORIES (US) 1999-02-11 WO disclosed
US-5026743-A Cationic polymers for electrodepositable coatings; polyepoxide, epoxy resin and polyether homo- and copolymers; smoothness IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-06-25 US disclosed
WO-1988007071-A1 IMPROVED FUEL OIL COMPOSITIONS EXXON CHEMICAL LIMITED (GB) 1988-09-22 WO disclosed
EP-0283294-A1 Improved fuel oil compositions EXXON CHEMICAL PATENTS INC. (US) 1988-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12534632-B2 Aqueous ink composition, printed material, and method of producing printed material TAF1L, VCL, NAP1L1 ESR1 3099/4885ALDH1A1 887/4885HSD17B10 3279/4885
US-20260125569-A1 WHITE INKJET INK ELMO1, MYO1G, MITF ESR1 3362/4885ALDH1A1 952/4885HSD17B10 2857/4885
US-12606716-B2 Biocide composition BBOX1, BRD1, LPO ESR1 4311/4885ALDH1A1 1274/4885HSD17B10 825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.